Charles Explorer logo
🇬🇧

Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative-GO SOAR)

Publication |
2021

Abstract

Background: The Global Gynaecological Oncology Surgical Outcomes Collaborative (GO SOAR) aims to develop a network of gynecological oncology surgeons, surgical departments, and other interested parties that will have the long-term ability to collaborate on outcome studies. The protocol for the first collaborative study is presented here.

Primary Objective: To evaluate international variation in 30-day post-operative morbidity and mortality following gynecological oncology surgery between very high/high and medium/low human development index country settings. Hypothesis: There is no variation in post-operative morbidity and mortality following gynecological oncology surgery between very high/high and medium/low human development index country settings.

Study Design: International, multicenter, prospective cohort study. Patient data will be collected over a consecutive 30-day period through gynecological oncology multidisciplinary teams/tumor boards and clinics across different human development index country groups.

All data are collected on a customized, secure, password protected, central REDCap database. Major Inclusion/Exclusion Criteria: Inclusion criteria include women aged >=18 years undergoing elective/emergency, curative/palliative surgery for primary/recurrent tubo-ovarian/peritoneal, endometrial, cervical, vulval, vaginal, gestational trophoblastic malignancies.

Surgical modality may be open, minimal access (laparoscopic/robotic), or vaginal. Primary Endpoint: 30-day post-operative morbidity and mortality defined as per Clavien-Dindo classification system.

Sample Size: 1100 (550/arm). Estimated Dates for Completing Accrual and Presenting Results: It is estimated recruitment will be completed by 2022 and results published by 2023.